BioVAT-HF Phase 1/2 Reveals First Evidence for Effective
Featured Late Breaking Clinical Science presentation at American Heart Association Scientific Sessions in PhiladelphiaSafe Maximal Dose Confirmed with...
United States Lothar Germeroth Wolfram Zimmermann Wolfram Hubertus Zimmermann German Center Cardiovascular Research
Source: globenewswire.com